Amphista Unveils AMX-883 Structure, Advances AML Drug into Phase I
Event summary
- Amphista Therapeutics disclosed the chemical structure of AMX-883, an orally bioavailable BRD9 degrader, at AACR 2026.
- AMX-883 demonstrated picomolar potency and selectivity in preclinical studies, targeting AML differentiation block.
- Phase I clinical trial for AML is set to begin in H2 2026.
- AMX-883 showed synergistic efficacy with venetoclax and prevented resistance in vitro.
The big picture
Amphista’s disclosure of AMX-883’s structure and mechanism underscores the growing focus on targeted protein degradation in oncology. The shift toward orally bioavailable, selective degraders like AMX-883 reflects broader industry trends in precision medicine, particularly for aggressive cancers like AML where current treatments often fail. The Phase I trial initiation in H2 2026 will be a key test of Amphista’s Eclipsys® platform’s ability to deliver differentiated therapeutics beyond CRBN and VHL-based approaches.
What we're watching
- Clinical Execution
- Whether AMX-883 can replicate preclinical efficacy in Phase I trials for AML.
- Market Differentiation
- How Amphista positions AMX-883 against existing AML treatments, particularly in karyotype-independent cases.
- Combination Therapy
- The pace at which Amphista advances AMX-883 in combination with venetoclax or other AML therapies.
Related topics